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ABSTRACT
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal
respiratory disease in humans. Eﬀorts to develop antibody-based therapies have focused on neutralizing antibodies
that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we
developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike
protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of
the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with
potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively,
these antibodies oﬀer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting
diﬀerent spike protein epitopes and functions.
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Introduction
Middle-East respiratory syndrome coronavirus (MERS-
CoV) is an emerging zoonotic virus that causes severe
and often fatal respiratory illness in humans. Since its
ﬁrst identiﬁcation in Saudi Arabia in 2012, the MERS-
CoV documented infections in humans steadily
increased, with 2298 cases as of February 2019 with an
estimated 35% lethality [1]. Dromedary camels are the
natural reservoir of MERS-CoV from which zoonotic
transmission can occur. A vast majority of dromedary
camels in the Arabian Peninsula appeared to be seropo-
sitive for MERS-CoV and MERS-CoV strains found in
epidemiologically-linked humans and dromedary
camels are nearly identical [2–5]. Human-to-human
transmission is ineﬃcient but can occur upon close con-
tact such as in household or hospital settings among
patients and from patients to health-care workers [2].
The high rate ofMERS-CoV infection in the dromedary
camel reservoir poses a persistent threat for reintroduc-
tion of MERS-CoV into humans.
Despite its continuous threat to public health, anti-
viral therapies or vaccines to treat or prevent MERS-
CoV infection are currently lacking. The viral spikes
on the surface of the enveloped MERS-CoV virions
are the primary antigenic target for the development
of vaccines and antibody therapies [6]. These spikes
mediate virus entry into host cells and consist of
three spike (S) glycoproteins, each containing the
receptor binding subunit S1 and the membrane-
anchored fusion-mediating subunit S2. Single-particle
cryo-electron microscopic analyses of trimeric S ecto-
domains of several coronaviruses, including MERS-
CoV [7–13], revealed a multi-domain architecture of
the S1 subunit, consisting of four core domains (desig-
nated A though D). For MERS-CoV, two of these spike
domains engage with host molecules to ensure entry
into target cells. The S1B domain of the MERS-CoV
spike protein binds the host receptor DPP4 which is
essential for cell entry [14,15], whereas the N-terminal
domain S1A binds to sialoglycans on mucins and on the
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host cell surface, which enhances infection of
MERS-CoV on human lung cells [16]. Three S2 sub-
units form the stem of the spikes, which can undergo
extensive conformational changes enabling membrane
fusion. The surface of the S2 subunit – to which anti-
bodies bind – shows a higher degree of sequence con-
servation than the more variable S1 subunit [7].
Several potently neutralizing human monoclonal
antibodies against MERS-CoV have been developed
using various approaches including single cell culturing
methods of memory B cells isolated from MERS-CoV
patients [17], hybridoma fusion of B-cells from immu-
nized transgenic mice encoding human variable immu-
noglobulin domains [18–20], and phage or yeast display
screening of Fab fragments of non-immune human
antibody libraries [21–23]. Some of these antibodies
showed protection againstMERS-CoV challenge in ani-
mal models [17, 19–22, 24–27]. All of these antibodies
were selected based on their in vitro neutralizing
capacity and most of them targeted the MERS-CoV
S1B receptor binding domain (RBD). Structural and
functional studies indicate that the epitopes of those
S1B-speciﬁc antibodies overlap with the DPP4 binding
site, explaining their potent neutralizing capacity [17,
19, 20, 28, 29]. So far only twomurine monoclonal anti-
bodies have been described that target theMERS-CoV S
outside the RBD [29]. Using a combination of DNA and
protein vaccination of mice, Wang et al, described S1-
speciﬁc non-RBD and S2-speciﬁc neutralizing murine
antibodies that showed potency for protection against
MERS-CoV in vivo [30]. Although RBD-speciﬁc anti-
bodies are undoubtly very potent in neutralizing
MERS-CoV, eﬀective antibody therapies are likely to
require the combination of neutralizing and non-neu-
tralizing antibodies, targeting multiple epitopes and
exhibiting diverse mechanisms of actions, including
Fc-mediated antibody eﬀector functions [31–33]. In
addition, such antibodies should preferably be human
to avoid an immune reaction against anti-MERS anti-
bodies of a diﬀerent species. Identiﬁcation of such pro-
tective antibodies, their targets and mechanisms of
activity is important for developing antibody-based
therapies against MERS-CoV.
In this study, we developed a set of human mono-
clonal antibodies against MERS-CoV with diverse mech-
anisms of action that show protective eﬃcacy in vivo. We
used the transgenic H2L2 mice encoding the human
immunoglobulin variable regions to generate antibodies
targeting the MERS-CoV spike protein (MERS-S).
From a large panel of MERS-S-speciﬁc H2L2 antibodies,
eight fully human monoclonal antibodies were generated
that bind non-overlapping epitopes on MERS-S with
high aﬃnity and interfere with the three known func-
tions of the viral protein: sialic acid binding, receptor
binding and membrane fusion. These antibodies were
shown to protect mice from a lethal MERS-CoV infec-
tion at low dosage. These studies extend our knowledge
on the protective value of monoclonal antibodies target-
ing – non-RBD – domains of MERS-S.
Results
Isolation of H2L2 antibodies targeting diﬀerent
domains of the MERS-CoV spike protein
To further our understanding of antibodies that con-
tribute to humoral immunity, we generated and
characterized a panel of human antibodies targeting
diﬀerent functional domains of the MERS-CoV spike
protein. To develop human monoclonal antibodies
(mAbs), we employed H2L2 transgenic mice carrying
immunoglobulin transgenes for human variable heavy
and light chains and rodent constant regions (http://
www.harbourbiomed.com). In one immunization
experiment, H2L2 mice were immunized with puriﬁed
MERS-S1 subunit (Figure 1(A), SI Appendix, Fig.
S1A). A second immunization experiment was done
to generate antibodies targeting the more conserved
MERS-S2 subunit using the MERS-S ectodomain
and MERS-S2 ectodomain as antigens following a
sequential immunization strategy (Figure 1(A), SI
Appendix, Figure S1A). Hybridoma cell lines were
generated from spleen and lymph node derived B-
cells from both immunization experiments and anti-
body-containing hybridoma supernatants were
screened for MERS-S reactivity by ELISA. The ﬁrst
immunization experiment provided 113 hybridoma
supernatants (out of 4553) that reacted to MERS-S1.
To understand the immunogenicity landscape of the
MERS-S1 subunit, we mapped epitopes of these anti-
bodies to S1 domains for which individual S1 domains
were expressed and used as antigens in ELISA (SI
Appendix, Figure S1B). The majority of S1-reactive
antibodies bound either to domain S1B (56%) or S1A
(38%) (Figure 1(B), SI Appendix, Fig. S2A). Four per-
cent of the S1-reactive antibodies bound to either
domain S1C or S1D, whereas some antibodies (2%)
did not bind to any of the S1 domains, indicative of
binding to interdomain epitopes (Figure 1(B), SI
Appendix, Figure S2A). The second immunization
with MERS-S ectodomain and MERS-S2 ectodomain
resulted in 50 hybridoma supernatants (out of 1158
hybridomas) that were positive for binding in a
MERS-S ectodomain ELISA. Most of the MERS-S
reactive antibodies bound to S1 (84%) and eight
(16%) were found to bind S2 (Figure 1(B)). Virus neu-
tralization activity of hybridoma supernatants was
screened using luciferase-encoding MERS-S pseudo-
typed vesicular stomatitis virus. Forty of the 113
MERS-S1-speciﬁc antibodies from MERS-S1-immu-
nized mice neutralized MERS-CoV infection (Figure
1(B), SI Appendix, Figure S2A). Notably, all of the
neutralizing antibody epitopes mapped to the receptor
binding domain S1B. Two out of the eight identiﬁed
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MERS-S2-speciﬁc antibodies were found to neutralize
MERS-S pseudovirus (Figure 1(B), SI Appendix,
Figure S2C). Screening the neutralizing antibodies
for antigen binding competition identiﬁed six epitope
groups, which was used for the selection of lead anti-
bodies (SI Appendix, Figure S2B).
Binding of lead human mAbs to the MERS-CoV
spike protein
From the set of MERS-CoV-S speciﬁc H2L2 anti-
bodies, a panel of eight monoclonal antibodies
(mAbs 1.10f3, 7.7g6, 1.6f9, 1.2g5, 1.8e5, 4.6e10,
Figure 1. Generation and characterization of monoclonal antibodies targeting the MERS-CoV spike protein. (A) The MERS-CoV spike
(S) protein and recombinant soluble MERS-CoV S antigens used for immunization of H2L2 transgenic mice to generate human
monoclonal antibodies (mAbs). Upper panel: Schematic representation of the MERS-CoV S protein, indicated are S subunits (S1
and S2), S1 domains (A through D), and known biological functions. Middle panel: Schematic representation of recombinant soluble
MERS-CoV S antigens, including the MERS-CoV S S1 subunit (MERS-S1), the ectodomain of its S2 subunit (MERS-S2ecto) or the entire
MERS-S ectodomain (MERS-Secto), the latter containing a mutation at the furin cleavage site at the S1/S2 junction and a C-terminally
fused T4 foldon trimerization tag to increase trimer stability (T4). Positions of signal peptides (SP) and StrepTag aﬃnity tags (ST) are
indicated. Lower panel: Immunization schedule H2L2 mice. To generate monoclonal antibodies (mAbs) targeting the MERS-CoV S
protein, groups of H2L2 mice (six mice/group) were immunized with either MERS-S1 (6×), or sequentially immunized with MERS-
Secto (3×), MERS-S2ecto (2×) and MERS-Secto (1x). Booster immunizations were done with two-week intervals and B-cells were har-
vested from spleen and lymph nodes four days after the last immunization. (B) Identiﬁed MERS-S1-reactive mAbs of hybridomas
derived from B-cells of S1-immunized H2L2 mice were characterized for epitope location and virus neutralization using MERS-S
pseudotyped VSV. Pie charts show mAb frequencies relative to the total (indicated in the centre circle). Domain-level epitope map-
ping was performed for MERS-S1-reactive mAbs and relative frequencies of mAbs binding to given S1 domains (S1A, S1B or S1CD)
are indicated. The percentage of mAbs that was reactive to S1 but not to the S1A, S1B or S1CD domains (S1other) is also shown. Virus
neutralization by S1-reactive mAbs was analysed using the luciferase-encoding MERS-CoV S pseudotyped VSV particles. (C) Ident-
iﬁed MERS-Secto-reactive mAbs of hybridomas generated from Secto/S2ecto immunized H2L2 mice were characterized for epitope
location and virus neutralization as in (B).
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1.6c7 and 3.5g6) were selected with epitopes distribu-
ted throughout diﬀerent domains of the MERS-CoV
spike protein for further detailed biophysical and
functional characterization. Selection of H2L2 mAbs
was based on their unique variable heavy and light
chain sequences, and on their capacity to neutralize
MERS-CoV relative to other mAbs within an epitope
group (SI Appendix, Figure S2C). We could not
detect MERS-S1A-speciﬁc neutralizing antibodies but
we nevertheless selected one non-neutralizing mAb
(1.10f3) that recognizes this sialic acid-binding
domain. Fully human mAbs were generated by clon-
ing the genes of the variable region of light and heavy
chain into human IgG1 expression vectors. Likewise,
IgG1 expression vectors were generated for the
expression of a previously reported potent MERS-
CoV-neutralizing antibody (anti-MERS control) as a
benchmark antibody [34]. In addition, we used an
irrelevant antibody recognizing the Strep-tag aﬃnity
tag (isotype control). All reformatted antibodies
were expressed in human HEK-293 T cells and pur-
iﬁed using Protein-A aﬃnity puriﬁcation (SI Appen-
dix, Figure S3).
Epitope mapping of puriﬁed human mAbs to the
diﬀerent domains of MERS-CoV S was done by
ELISA using soluble MERS-CoV Secto, S1, S1A, S1B
or S2ecto as antigens (Figure 2(A), SI Appendix,
Figure S1B). Domain-level epitope mapping
conﬁrmed that mAb 1.10f3 bound to the sialic acid
binding domain S1A, mAbs 7.7g6, 1.6f9, 1.2g5, 1.8e5
and 4.6e10 targeted the receptor binding domain
S1B whereas mAbs 1.6c7 and 3.5g6 bound the ectodo-
main of the membrane fusion subunit S2 (Figure 2
(A)). Next competition for binding of the lead anti-
bodies to the MERS-S ectodomain was tested using
bio-layer interferometry (Figure 2(B)). The binding
competition data indicated the existence of six epi-
tope groups suggesting the presence of six distinct
epitopes targeted by the eight lead mAbs on the
MERS-CoV S protein: group I (7.7g6, 1.6f9 and
Figure 2. Human anti-MERS-S mAbs targeting six epitope groups distributed over multiple domains of the MERS-CoV spike protein.
(A) ELISA reactivity of the human anti-MERS-S mAbs to the indicated MERS-CoV spike glycoprotein domains. (B) Binding compe-
tition of anti-MERS-S mAbs analysed by bio-layer interferometry (BLI). Immobilized MERS-Secto antigen was saturated in binding
with a given anti-MERS-S mAb (step 1) and then exposed to binding by a second mAb (step 2). Additional binding of the second
antibody indicates the presence of an unoccupied epitope, whereas lack of binding indicates epitope blocking by the ﬁrst antibody.
As a control, the ﬁrst mAb was also included in the second step to check for self-competition. (C) Schematic distribution of epitope
groups of anti-MERS-S mAbs over the diﬀerent MERS-S domains.
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1.2g5), group II (1.8e5) and group III (4.6e10) on the
S1B domain, group IV (1.10f3) on the S1A domain,
and groups V (1.6c7) and group VI (3.5g6) on the
S2 ectodomain. Antibodies of diﬀerent groups com-
peted minimally with each other, indicating that
their epitopes were largely distinct (Figure 2(B) and
(C)). The binding kinetics of the eight human mono-
clonal antibodies was determined by bio-layer inter-
ferometry. Strep-tagged MERS-S ectodomain was
captured on the protein-A sensor via an anti-Streptag
antibody and kinetic binding parameters of antibodies
were determined at 25°C and pH 7.4. All antibodies
displayed high aﬃnity binding for the MERS-S ecto-
domain with equilibrium dissociation constants (KD)
in the nano- to the picomolar range (0.081 to
4.78 nM) (Table 1, SI Appendix, Figure S4). The
binding aﬃnity of the MERS-CoV receptor DPP4 to
MERS-S was measured in the same set up, and was
lower compared to the binding aﬃnity of the mAbs
that target the receptor binding domain S1B (Table
1, SI Appendix, Figure S4).
Anti-MERS-S mAbs bind cell surface displayed
MERS-CoV spike protein
To assess whether the lead mAbs can bind full-length
MERS-CoV S expressed on the cell surface, we trans-
fected Huh-7 cells with plasmid encoding MERS-
CoV S. The spike gene was C-terminally extended
with GFP to monitor MERS-S expression, and
mutated at the furin cleavage site to stabilize the
spike protein in its native prefusion state and to pre-
vent MERS-S-mediated cell–cell fusion. Binding of
lead mAbs to cell-surface expressed MERS-S was
analysed by ﬂow cytometry and immunoﬂuorescence.
All anti-MERS-S mAbs bound to non-permeabilized,
MERS-S transfected (GFP-positive) Huh-7 cells in
both assays, indicative for binding to cell surface
displayed MERS-CoV S (SI Appendix, Figures S5
and S6).
Neutralization activity of anti-MERS-S mAbs
The ability of human lead mAbs to neutralize MERS-
CoV infection in vitro was tested on Vero cells with
luciferase-encoding MERS-S pseudotyped virus, and
with authentic MERS-CoV using a plaque reduction
neutralization test (PRNT). Levels of virus neutraliz-
ation varied among the individual antibodies (Figure 3
(A) and Table 2). The 7.7g6, 1.6f9 and 1.2g5 mAbs all
targeting epitope group I on MERS-S1B showed the
most potent neutralizing activity, and displayed pico-
molar half-maximal inhibitory concentrations against
MERS-S pseudotyped virus (IC50 = 7–30 pM) and
authentic MERS-CoV (PRNT50 = 53–200 pM), which
was equivalent to or lower than our benchmark
MERS-S neutralizing monoclonal antibody that targets
the same domain (Table 2). MERS-S1B mAbs from epi-
tope group II (mAb 1.8e5) and III (mAb 4.6e10)
Table 1. Binding kinetics of mAbs/MERS-Secto or DPP4/MERS-
Secto from bio-layer interferometry measurements.
mAb KD (M) kon (M
−1 sec−1) koﬀ (sec
−1)
7.7g6 3.612 × 10−10 3.196 × 104 1.154 × 10−5
1.6f9 5.298 × 10−10 1.175 × 104 6.227 × 10−6
1.2g5 8.086 × 10−11 7.587 × 104 6.134 × 10−6
1.8e5 3.178 × 10−10 2.442 × 104 4.232 × 10−6
4.6e10 3.592 × 10−10 3.569 × 104 1.134 × 10−5
1.10f3 4.784 × 10−9 9.550 × 103 4.569 × 10−5
1.6c7 5.007 × 10−10 5.927 × 104 2.968 × 10−5
3.5g6 2.246 × 10−9 2.107 × 104 4.733 × 10−5
α-MERS-CTRL 1.289 × 10−10 4.576 × 104 5.900 × 10−6
DPP4 3.416 × 10−9 1.423 × 104 4.859 × 10−5
Figure 3. Virus neutralization and receptor binding inhibition
by anti-MERS-S mAbs. (A) Analysis of MERS-CoV neutralizing
activity by anti-MERS-S mAbs using MERS-S pseudotyped, luci-
ferase-encoding VSV. A previously described RBD-speciﬁc,
MERS-CoV-neutralizing human monoclonal antibody (anti-
MERS-CTRL) and irrelevant isotype monoclonal antibody (Iso-
CTRL) were included as positive and negative control, respect-
ively. Luciferase-expressing VSV particles pseudotyped with the
MERS-CoV S protein or authentic MERS-CoV were incubated
with antibodies at the indicated concentrations and the mix
was used to transduce Huh-7 cells. At 24 h postinfection luci-
ferase expression was measured and neutralization (%) was cal-
culated as the ratio of luciferase signal relative to relative to
non-antibody-treated controls. Data represent the mean (±
standard deviation, SD) of three independent experiments.
(B) Receptor binding inhibition by anti-MERS-S mAbs, deter-
mined by an ELISA-based assay. Recombinant soluble MERS-
Secto was preincubated with serially diluted anti-MERS-S
mAbs and added to ELISA plates coated with soluble the
MERS-CoV S ectodomain. Binding of MERS-Secto to DPP4 was
measured using HRP-conjugated antibody recognizing the
Streptag aﬃnity tag on DPP4. Data represent the mean (± stan-
dard deviation, SD) of three independent experiments.
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neutralized MERS-S pseudovirus infection at nanomo-
lar concentrations (IC50 = 10 and 0.32 nM, resp.), and
exhibited no detectable or moderate neutralizing
activity against authentic MERS-CoV (PRNT50 = >
6.67 and 6.67 nM, resp.). The MERS-S1A-speciﬁc
mAb 1.10f3 lacked MERS-CoV neutralization activity
in both virus neutralization assays. The anti-MERS-
S2 mAbs 1.6c7 and 3.5g6 were able to neutralize
MERS-S pseudovirus (IC50 = 2.45 and 16.6 nM,
resp.), albeit at higher concentrations than the most
potent neutralizing MERS-S1B mAbs (about 100-fold
higher). The isotype control did not show any neutral-
ization in both assays. Collectively, our data demon-
strate that antibodies targeting the receptor binding
domain S1B of the MERS-CoV spike protein display
the highest potential for neutralization of MERS-CoV
infection in vitro.
Anti-MERS-S1B mAbs neutralize MERS-CoV by
blocking receptor binding
To understand the mechanism of action of lead mAbs,
we set up assays to assess antibody interference with
the diverse functions of the MERS-CoV S domains.
To assess whether antibodies can compete with viral
binding to the host receptor DPP4, we developed an
ELISA-based receptor binding inhibition assay, in
which binding of MERS-S ectodomain to DPP4-coated
ELISA plates is quantiﬁed and interference with recep-
tor binding by antibodies is measured as a reduction in
binding signal. In the absence of antibodies, the MERS-
S ectodomain showed stable binding to DPP4 (Figure 3
(B)). Whereas anti-MERS-S1B mAb 1.8e5 showed weak
interference with binding of MERS-S ectodomain to
DPP4, all other MERS-S1B-speciﬁc mAbs (mAbs
7.7g6, 1.6f9, 1.2g5, 4.6e10 and anti-MERS-CTRL)
potently inhibited binding of MERS-S ectodomain to
DPP4 in a concentration-dependent manner (Figure 3
(B)). The data indicate that these antibodies partly
overlap with or bind suﬃciently close to the receptor-
binding site on S1B to compete with receptor binding.
None of the antibodies that bind outside the RBD
domain (MERS-S1A and -S2) could block receptor
binding. The potency of the S1B-speciﬁc mAbs to inhi-
bit receptor binding corresponds with the ability of
these antibodies to neutralize virus infection
(Table 2), indicating that the inhibition of virus–recep-
tor interaction by these antibodies is their main mech-
anism of neutralization in vitro.
Anti-MERS-S1A mAb 1.10f3 blocks binding of
MERS-S1A to sialoglycoconjugates
Recently we demonstrated that the MERS-S1A domain
facilitates viral binding to cell-surface sialoglycoconju-
gates, which can serve as a cell attachment factor for
MERS-CoV [16]. We assessed whether the MERS-
S1A-targeting mAb 1.10f3 can interfere with binding
of MERS-S1A to sialoglycoconjugates on the surface of
erythrocytes using the hemagglutination inhibition
assay. To this end, we used lumazine synthase (LS)
nanoparticles multivalently displaying MERS-S1A
(S1A-LS), which were earlier employed to demonstrate
the sialic-acid dependent hemagglutination by the
MERS-S1A domain [16]. Hemagglutination was
observed when S1A-LS was mixed with erythrocytes
(Figure 4(A)). S1A-LS mediated hemaglutination was
abrogated upon addition of the MERS-S1A mAb
1.10f3, but not upon addition of the isotype control.
Next, we assessed whether interference of 1.10f3 with
binding to sialylated receptors could inhibit Sia-depen-
dentMERS-CoV infection. Binding to sialoglycansmay
aidMERS-CoV entry into DPP4-positive cells, depend-
ing on the cell type. Infection of Vero cells does not
depend on cell surface sialic acids, concurrent with a
low abundancy of the MERS-CoV S1A glycotopes on
those cells [16]. Correspondingly, infection of Vero
cells with MERS-S pseudovirus could not be inhibited
by 1.10f3 (Figure 4(B)). By contrast, infection of
human lung Calu-3 cells was shown to rely on cell sur-
face sialic acids which correlated with the abundance of
MERS-CoV S1A receptors [16]. Contrary to Vero cells,
infection of Calu-3 cells could be inhibited by 1.10f3
(Figure 4(B)) suggesting that antibody binding to
MERS-S1A can neutralize MERS-CoV infection via
inhibition of virus binding to cell surface sialoglycans.
Table 2. Virus neutralization and receptor binding inhibition by anti-MERS-S mAbs.
mAb MERS-S target
IC50* MERS-S VSVpp PRNT50** MERS-CoV RBI50***
μg/ml nM μg/ml nM μg/ml nM
7.7g6 S1B 0.001 0.007 0.008 0.053 0.007 0.047
1.6f9 0.006 0.04 0.03 0.200 0.013 0.087
1.2g5 0.002 0.013 0.03 0.200 0.014 0.093
1.8e5 1.500 10 >1 >6.67 >10 >66.7
4.6e10 0.048 0.320 1 6.667 0.137 0.913
1.10f3 S1A >10 > 66.7 >1 >6.67 >10 >66.7
1.6c7 S2A 0.367 2.447 1 6.67 >10 >66.7
3.5g6 2.488 16.6 >1 >6.6 >10 >66.7
α-MERS-CTRL S1B 0.005 0.033 0.03 0.200 0.022 0.147
Iso-CTRL – >10 > 66.7 >1 >6.67 – –
* IC50: mAb concentration resulting in half-maximal infection of MERS-S VSV pseudovirus (MERS-S VSVpp) on Vero cells.
** PRNT50: highest mAb dilution resulting in > 50% reduction in the number of MERS-CoV infected Vero cells.
*** RBI50: mAb concentration of that gives half-maximal receptor binding.
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Anti-MERS-S2 mAbs interfere with MERS-S
mediated membrane fusion
The coronavirus S2 subunit encompasses the machin-
ery for fusion of viral and host cell membranes, a pro-
cess that is driven by extensive refolding of the
metastable prefusion S2 into a stable postfusion state
[35]. We hypothesized that antibodies targeting the
MERS-S2 subunit might neutralize MERS-CoV infec-
tion by inhibiting this fusion process. To test this, we
developed a MERS-CoV-S driven cell–cell fusion
assay using a modiﬁed MERS-CoV spike protein. To
monitor expression of MERS-CoV S in cells, we
extended the viral fusion protein C-terminally with
GFP. In addition, we mutated the furin cleavage site
at the S1/S2 junction to increase the dependency of
MERS-CoV S fusion activation on exogenous addition
of trypsin. Expression of this MERS-S variant upon
transfection of DPP4-expressing Huh-7 cells could be
readily observed by the GFP signal (Figure 4(C)).
Upon addition of trypsin, large GFP-ﬂuorescent syncy-
tia were detected indicating MERS-S mediated cell–cell
fusion (Figure 4(C)). As expected, the addition of anti-
MERS-S1B (7.7g6) blocked the formation of syncytia
since cell–cell fusion is dependent on receptor inter-
action. No eﬀect on syncytium formation was seen
for the MERS-S1A mAb 1.10f3. In contrast, the
MERS-S2-speciﬁc mAbs 1.6c7 and 3.5g6 both blocked
syncytium formation. Since both neutralizing anti-
bodies did not interfere with receptor binding (Figure 3
(B)), we surmise that binding of these S2-speciﬁc anti-
bodies inhibits infection by preventing conformational
changes in the S2 subunit of the MERS-CoV spike
protein that are required for fusion.
Figure 4. Anti-MERS-S mAbs targeting MERS-S1A and -S2 domains block domain-speciﬁc functions. (A) The anti-MERS-S1A mAb
1.10f3 interferes with MERS-S1A-mediated sialic acid binding, determined by a hemagglutination inhibition assay [16]. The sia-
lic-acid binding domain S1A of MERS-S was fused to lumazine synthase (LS) protein that can self-assemble to form 60-meric nano-
particle (S1A-LS), which enables multivalent, high aﬃnity binding of the MERS-S1A domain to sialic acid ligands such as on
erythocytes. Human red blood cells were mixed with S1A-LS in the absence or presence of 2-fold dilutions of the MERS-S1A-speciﬁc
mAb 1.10f3. Isotype control antibody was included as a negative control. Hemagglutination was scored after 2 h of incubation at 4°
C. The hemagglutination inhibition assay was performed three times, a representative experiment is shown. (B) Neutralization of
MERS-S pseudotyped VSV by anti-MERS-S mAb 1.10f3 on Vero and Calu-3 cells. Data represent the mean (± standard deviation, SD)
of three independent experiments. (C) The anti-MERS-S2 mAbs 1.6c7 and 3.5g6 block MERS-S-mediated cell–cell fusion. Huh-7 cells
were transfected with plasmid expressing MERS-CoV S, C-terminally fused to GFP. Two days after transfection, cells were treated
with trypsin to activate membrane the fusion function of the MERS-CoV S protein, and incubated in the presence or absence of anti-
MERS-S2 mAbs 1.6c7 and 3.5g6, or the anti-MERS-S1B mAb 7.7g6 and anti-MERS-S1A 1.10f3, all at 10 μg/ml. Formation of MERS-S
mediated cell–cell fusion was visualized by ﬂuorescence microscopy. Merged images of MERS-S-GFP expressing cells (green) and
DAPI-stained cell nuclei (blue) are shown. Experiment was repeated two times and representative images are shown.
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Protective activity of mAbs from lethal MERS-
CoV challenge
To assess the prophylactic eﬃcacy of our lead mAbs
against MERS-CoV infection in vivo, we used trans-
genic K18-hDPP4 mice expressing human DPP4 [36].
Six hours prior to MERS-CoV infection, mice (5
mice/group) were injected intraperitoneally with a
50 μg dose of each mAb (equivalent to 1.8 mg mAb
per kg body weight). The percentage of survival and
weight change following challenge was monitored for
12 days. MERS-CoV infection was consistently lethal
as all mice that received the monoclonal isotype control
showed signiﬁcant weight loss and had succumbed to
the infection between 7 and 8 days post-challenge
(Figure 5(A) and (B)). Contrarily, all MERS-S1B bind-
ing mAbs showed high levels of protection against
lethal MERS-CoV challenge (80–100%, Figure 5).
Anti-MERS-S1B mAbs 7.7g6, 1.2g5 and the benchmark
anti-MERS control mAb uniformly protected animals
from death, whereas the MERS-S1B mAbs 1.6f9,
1.8e5 and 4.6e10 protected 4 out of 5 animals (80%)
in this model. The MERS-S1A binding mAb 1.10f3
aﬀorded partial protection frommortality (40%). Nota-
bly, the anti-MERS-S2 mAbs 1.6c7 and 3.5g6 protected
all ﬁve animals from lethal infection. Relative to the
isotype control treated mice, mice treated with
MERS-S speciﬁc antibodies showed reduced weight
loss (Figure 5(B)). These results highlight that anti-
bodies targeting non-RBD domains (i.c. S1A and S2)
of the MERS-CoV spike protein can contribute to
humoral immunity against MERS-CoV infection.
Discussion
The recurring spillover infections of MERS-CoV in
humans from its dromedary camel reservoir, the high
mortality and person-to-person transmission pose a
signiﬁcant threat to public health. As there are cur-
rently no licensed vaccines or treatments for combat-
ting MERS-CoV infections, the development of
Figure 5. Human anti-MERS-S mAbs protect mice against lethal MERS-CoV challenge. (A–B) Fifty microgram of antibody (equivalent
to 1.8 mg mAb/kg body weight) was infused intraperitoneally in K18-hDPP4-transgenic mice 6 h before challenge with 5 × 103 pfu/
mice of MERS-CoV. Five mice per group were used in the experiment. Survival rates (A) and weight loss (B) (expressed as a per-
centage of the initial weight) was monitored daily until 12 days post-inoculation.
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eﬀective counter measures is a critical need, and
recently prioritized by the World Health Organization
in the research and development Blueprint for action to
prevent epidemics [37]. Antibody therapies targeting
critical entry functions of viral glycoproteins are
increasingly recognized as promising antiviral strat-
egies to protect humans from lethal disease [38]. For
MERS-CoV, passive immunization studies with neu-
tralizing antibodies in small animals support the idea
that antibody therapies may hold promise to protect
humans from lethal MERS-CoV mediated disease.
Most of these protective antibodies neutralize virus
infection by occupying the receptor binding domain
(RBD) and compete with the host receptor. Here we
describe the protective activity of individual human
antibodies targeting RBD as well as non-RBD spike
domains and their interference with the three known
functions of the spike glycoprotein. Collectively, the
arsenal of protective antibodies that bind to and func-
tionally inhibit the activity of multiple spike protein
domains can reveal new ways to gain humoral protec-
tion against the emerging MERS coronavirus.
Potent MERS-CoV neutralizing antibodies, as our
study and that of others have shown, commonly target
the S1B receptor binding domain [17–23]. The anti-S1B
antibodies physically prevent binding to the host receptor
DPP4 attributed to their higher binding aﬃnity for
MERS-S, thereby potently neutralizing MERS-CoV
infection. The ﬁve S1B-speciﬁc antibodies identiﬁed in
this study were found to target three non-overlapping
epitope groups on the MERS-CoV S1B domain, consist-
ent with the three epitope groups at the spike-DPP4
receptor interface reported by Tang et al. [22]. These
S1B antibodies displayed varying neutralization potency
with 100-1000-fold diﬀerences in IC50 values, with anti-
bodies targeting epitope group I showing ultrapotent
neutralizing activity at sub-nanomolar levels. Irrespective
of the neutralizing potency, all S1B antibodies displayed
signiﬁcant protective activity (80–100% survival rates)
in mice from lethal MERS-CoV challenge.
Apart from engaging the host receptor DPP4, we
earlier demonstrated that the MERS-CoV spike protein
binds sialoglycoconjugates (Sia’s) on mucins and the
host cell surface via an independently functional
domain, the N-terminal domain S1A. This Sia-binding
activity serves as an attachment factor for MERS-CoV
infection in a cell-type dependent manner [16]. We
now show that binding of the isolated mAb 1.10f3 to
this MERS-S1A domain abrogates Sia-binding, and
can inhibit the Sia-dependent infection of human
lung Calu-3 cells by MERS-CoV [16]. Moreover, pas-
sive immunization of mice with this MERS-S1A-
speciﬁc mAb resulted in 40% protection frommortality
following MERS-CoV infection. These ﬁndings under-
line the role of sialic acid binding for MERS-CoV infec-
tion in vivo, and demonstrate the importance of anti-
MERS-S1A antibodies in protection.
From all MERS-CoV mAbs described, only two
mAbs – G2 and G4 – targeted epitopes outside the
RBD [29]. G2 binds an epitope in S1 outside the
RBD, whereas G4 targets a variable loop in S2 (Wang
2015). Both murine antibodies were shown to protect
mice from a lethal infection of MERS-CoV in vivo.
Both antibodies were neutralizing, though the interfer-
ence of these antibodies with spike functions was not
delineated. Using a tailored immunization scheme to
boost antibody responses to the MERS-CoV fusion-
mediating S2 subunit, we were able to recover MERS-
S2-speciﬁc mAbs, two of which demonstrated neutra-
lizing activity and fully protected mice from a lethal
MERS-CoV challenge. These two S2 antibodies did
not interfere with receptor binding yet abrogated
cell–cell fusion, implying their interference with
spike-mediated membrane fusion by preventing con-
formational changes required for fusion. The highly
protective S2 mAbs only displayed modest in vitro neu-
tralizing activity, indicating that strong neutralizing
activity is not a prerequisite for protection.
Apart from interfering with functions of viral pro-
teins, antibodies are able to employ a broad range of
antiviral activities through the innate immune system.
Binding of antibodies to glycoproteins on the surface of
infected cells or on viruses may decorate them for
destruction through Fc-mediated antiviral activities
including antibody-dependent cellular cytotoxicity
(ADCC), antibody-dependent cell-mediated phagocy-
tosis (ADCP) or complement-dependent cytotoxicity
(CDC) [39]. These functions may be irrespective of
the neutralization capacity of antibodies as long as
they can bind surface antigens on the infected cell.
Congruent with this prerequisite, all of the anti-
MERS-S antibodies were able to bind cell surface dis-
played spikes. In addition, our human antibodies
were of the IgG1 isotype which was shown to be the
most potent human IgG isotype in mice showing
eﬃcient binding to all activating mouse Fcγ receptors
and induction of ADCC/ADCP with mouse natural
killer cells and mouse macrophages [40]. Further
research is needed to deﬁne the contribution of Fc-
functions to antibody-mediated protection from
MERS-CoV infection.
We identiﬁed human antibodies targeting six dis-
tinct epitope classes across diﬀerent domains of the
MERS-CoV spike protein, each of which showing pro-
tective activity in mice against lethal MERS-CoV chal-
lenge. This discovery holds promise for the
development of antibody therapeutics against MERS-
CoV infection. Passive immunization with a combi-
nation of antibodies targeting diﬀerent domains and
functions of the viral glycoprotein might be more pro-
tective against virus infection than single epitope mAb
therapy, as was shown for other enveloped RNA
viruses [31, 32, 41–43]. Which combination of anti-
bodies provides synergistic protective activity against
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MERS-CoV and which combination of epitopes is the
best to target needs to be further evaluated. In addition,
combinations of antibodies targeting distinct epitopes
can mitigate viral antigenic escape as has been demon-
strated for a number of viruses including MERS-CoV
[30, 43–45]. Particularly, the use of (combinations of)
antibodies targeting conserved epitopes in the spike
glycoprotein that are critical for viral entry may further
decrease chances of escape mutants. Such antibodies
may as well oﬀer cross-protection against related
viruses. Antibodies targeting conserved epitopes in
the stem regions of glycoproteins of the enveloped
virus including inﬂuenza virus and ebolavirus oﬀer
protection against a wide range of antigenically distinct
variants [46–48]. Likewise, the generation of antibodies
targeting the conserved S2 stem of the coronavirus
spike protein that can cross-bind spikes of related cor-
onaviruses may even allow the development of mAbs
with broad protection against related future emerging
coronaviruses. Furthermore, it is important that the
antibodies we describe are completely human, which
has the important advantage that they can be used sev-
eral times in the same host without invoking an
immune response against the antibody as may be
required for people working with camels or infected
patients.
Finally, the presence of protective antibody epitopes
in multiple spike domains, suggests that multi-domain
approaches of spike-based vaccines may provide a
broader repertoire of immune responses compared to
RBD-focused vaccine antigen and reduce the risk of
antigenic escape. This study also deﬁnes diﬀerent cor-
relates of humoral protection, which may need to be
considered in the evaluation of vaccine-induced
immune responses.
Materials and methods
Production of recombinant MERS-CoV S proteins. A
gene encoding the MERS-CoV spike glycoprotein
(EMC isolate; GenBank YP_009047204.1) was syn-
thesized by GenScript USA Inc. and the sequence was
codon-optimized tomaximize expression in the baculo-
virus expression system. To produce soluble MERS-S
ectodomain, the gene fragment encoding the MERS-
CoV S ectodomain (amino acid 19–1262) was cloned
in-frame between honeybee melittin (HBM) secretion
signal peptide and T4 ﬁbritin (foldon) trimerization
domain followed by Strep-tag puriﬁcation tag in the
pFastbac transfer vector (Invitrogen). The furin clea-
vage site R747SVR751 at the S1/S2 junction was mutated
to KSVR, to prevent cleavage by furin at this position.
The genes encoding MERS-S1 subunit (amino acid
19-748), MERS-S2 ectodomain (amino acid 752-
1262), MERS-S1A (amino acid 19-357), and MERS-
S1B [358–588] were cloned in-frame between the
HBM secretion signal peptide and a triple StrepTag
puriﬁcation tag in the pFastbac transfer vector. Gener-
ation of bacmid DNA and recombinant baculovirus
was performed according to protocols from the Bac-
to-Bac system (Invitrogen) and expression of MERS-
CoV S variants was performed by infection of recombi-
nant baculovirus of Sf-9 cells. Recombinant proteins
were harvested from cell culture supernatants 3 days
post infection and puriﬁed using StrepTactin sepharose
aﬃnity chromatography (IBA). The soluble MERS-S
ectodomain used for immunization was produced in
the Drosophila expression system as described before
[7], by cloning the gene insert from the pFastbac transfer
vector into the pMT expression vector (Invitrogen,
Thermo Fisher Scientiﬁc, the Netherlands). Production
of recombinant MERS-S1 (amino acid 1-747) used for
immunization, and of soluble DPP4 was described pre-
viously [15]. In brief, the MERS-S1 (amino acid 1-747)
encoding sequence was C-terminally fused to a gene
fragment encoding the Fc region of human IgG and
cloned into the pCAGGS mammalian expression vec-
tor, expressed by plasmid transfection in HEK-293 T
cells, and aﬃnity puriﬁed from the culture supernatant
using Protein-A aﬃnity chromatography. The Fc part of
S1-Fc fusion protein was proteolytically removed by
thrombin following Protein-A aﬃnity puriﬁcation
using the thrombin cleavage site present at the S1-Fc
junction. The sequence encoding the human DPP4
ectodomain (amino acid 39–766) N-terminally fused
to the Streptag puriﬁcation tag was cloned into the
pCAGGS vector, expressed by plasmid transfection of
HEK-293 T cells and puriﬁed from the cell culture
supernatant using StrepTactin sepharose aﬃnity
chromatography. Production of lumazine synthase
(LS) nanoparticles displaying the MERS-CoV spike
domain S1A (S1A-LS) has been described previously
[16]. In brief, the MERS-S1A encoding sequence (resi-
dues 19–357) was N-terminally fused to a CD5 signal
peptide sequence, followed by a Streptag puriﬁcation
tag sequence (IBA) and C-terminally fused to the luma-
zine synthase-encoding sequence fromAquifex aeolicus
(GenBank WP_010880027.1) via a Gly-Ser linker, and
subsequent cloned into the pCAGGS vector, expressed
in HEK-293 T cells and puriﬁed from the cell culture
supernatant using StrepTactin aﬃnity chromatography.
Production of recombinant monoclonal antibodies.
For recombinant mAb production, cDNA’s encoding
the variable heavy (VH) and light (VL) chain regions
of anti-MERS-S H2L2 mAbs were cloned into
expression plasmids containing the human IgG1
heavy chain and Ig kappa light chain constant regions,
respectively (Invivogen). Both plasmids contain the
interleukin-2 signal sequence to enable eﬃcient
secretion of recombinant antibodies. Synthetic VH
and VL gene fragments of the benchmark antibody
(MERS-CTRL) were synthezised based on previously
described sequences for the MERS-S monoclonal anti-
body “H1H15211P” [34]. Recombinant human anti-
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MERS-S antibodies were produced in HEK-293 T cells
following transfection with pairs of the IgG1 heavy and
light chain expression plasmids according to protocols
from Invivogen. Antibodies were puriﬁed from tissue
culture supernatants using Protein-A aﬃnity chrom-
atography. Puriﬁed antibodies were stored at 4°C
until use.
Generation of anti-MERS-S H2L2 mAbs. Two
groups of six H2L2 mice were immunized in two
weeks intervals six times with puriﬁed MERS-S1
(group I) and MERS-S ectodomain followed by
MERS-S2 ectodomain (group II) as outlined in Figure
1(A). Antigens were injected at 20 μg/mouse using Sti-
mune Adjuvant (Prionics) freshly prepared according
to the manufacturer instruction for the ﬁrst injection,
while boosting was done using Ribi (Sigma) adjuvant.
Injections were done subcutaneously into the left and
right groin each (50 μl) and 100 μl intraperitoneally.
Four days after the last injection, spleen and lymph
nodes are harvested, and hybridomas made by a stan-
dard method using SP 2/0 myeloma cell line
(ATCC#CRL-1581) as a fusion partner. Hybridomas
were screened in antigen-speciﬁc ELISA and those
selected for further development, subcloned and pro-
duced on a small scale (100 ml of medium). For this
purpose, hybrydomas are cultured in serum- and
protein-free medium for hybridoma culturing
(PFHM-II (1X) Gibco) with the addition of non-essen-
tial amino acids (100× NEAA, Biowhittaker Lonza Cat
BE13-114E). Antibodies were puriﬁed from the cell
supernatant using Protein-G aﬃnity chromatography.
Puriﬁed antibodies were stored at 4°C until use.
MERS-S pseudotyped virus neutralization assay.
Production of VSV pseudotyped with MERS-S was
performed as described previously with some adap-
tations [49]. Brieﬂy, HEK-293 T cells were transfected
with a pCAGGS expression vector encoding MERS-S
carrying a 16-a.a. cytoplasmic tail truncation. One
day post transfection, cells were infected with the
VSV-G pseudotyped VSVΔG bearing the ﬁreﬂy (Photi-
nus pyralis) luciferase reporter gene [49]. Twenty four
hours later, MERS-S-VSVΔG pseudotypes were har-
vested and titrated on African green monkey kidney
Vero cells. In the virus neutralization assay, MERS-S
mAbs were serially diluted at two times the desired
ﬁnal concentration in DMEM supplemented with 1%
foetal calf serum (Bodinco), 100 U/ml Penicillin and
100 µg/ml Streptomycin. Diluted mAbs were incubated
with an equal volume of MERS-S-VSVΔG pseudotypes
for 1 h at room temperature, inoculated on conﬂuent
Vero monolayers in 96-well plated, and further incu-
bated at 37°C for 24 h. Luciferase activity was
measured on a Berthold Centro LB 960 plate lumin-
ometer using D-luciferin as a substrate (Promega).
The percentage of infectivity was calculated as the
ratio of luciferase readout in the presence of mAbs nor-
malized to luciferase readout in the absence of mAb.
The half maximal inhibitory concentrations (IC50)
were determined using 4-parameter logistic regression
(GraphPad Prism v7.0).
MERS-CoV neutralization assay. Neutralization of
authentic MERS-CoV was performed using a plaque
reduction neutralization test (PRNT) as described ear-
lier [50]. In brief, mAbs were two-fold serially diluted
and mixed with MERS-CoV for 1 h. The mixture was
then added to Huh-7 cells and incubated for 1 hr,
after which the cells were washed and further incubated
in medium for 8 h. Subsequently, the cells were
washed, ﬁxed, permeabilized and the infection was
detected using immunoﬂuorescent staining. The
PRNT titre was determined as the highest mAb
dilution resulting in a > 50% reduction in the number
of infected cells (PRNT50).
ELISA analysis of MERS-CoV S binding by anti-
bodies. NUNC Maxisorp plates (Thermo Scientiﬁc)
were coated with the indicated MERS-CoV antigen at
100 ng /well at 4°C overnight. Plates were washed
three times with Phosphate Saline Buﬀer (PBS) con-
taining 0.05% Tween-20 and blocked with 3% Bovine
Serum Albumin (BSA) in PBS containing 0.1%
Tween-20 at room temperature for 2 h. Four-folds
serial dilutions of mAbs starting at 10 µg/ml (diluted
in blocking buﬀer) were added and plates were incu-
bated for 1 h at room temperature. Plates were washed
three times and incubated with HRP-conjugated goat
anti-human secondary antibody (ITK Southern Bio-
tech) diluted 1:2000 in blocking buﬀer for one hour
at room temperature. HRP activity was measured at
450 nm using tetramethylbenzidine substrate (BioFX)
and an ELISA plate reader (EL-808, Biotek).
ELISA analysis of receptor binding inhibition by
antibodies. Recombinant soluble DPP4 was coated
on NUNC Maxisorp plates (Thermo Scientiﬁc) at 4°
C overnight. Plates were washed three times with
PBS containing 0.05% Tween-20 and blocked with
3% BSA in PBS containing 0.1% Tween-20 at room
temperature for 2 h. Recombinant MERS-CoV S ecto-
domain and serially diluted anti-MERS mAbs were
mixed for 1 h at RT, added to the plate for 1 h at
room temperature, after which plates were washed
three times. Binding of MERS-CoV S ectodomain to
DPP4 was detected using HRP-conjugated anti-Strep-
MAb (IBA) that recognizes the Streptag aﬃnity tag
on the MERS-CoV S ectodomain. Detection of HRP
activity was performed as described above.
Antibody competition assay. Competition among
mAbs for binding to the same epitope on MERS-CoV
S was determined using Bio-Layer Interferometry
(BLI) on Octet QK (Pall ForteBio) at 25°C. All reagents
were diluted in PBS. The assay was performed following
these steps: (1). anti-Strep mAb (50 μg/ml) was coated
on Protein A biosensor (Pall ForteBio) for 30 mins,
(2) blocking of sensor with rabbit IgG (50 μg/ml) for
30 mins, (3). Recombinant Strep-tagged MERS-CoV S
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ectodomain (50 μg/ml) was immobilized to the sensor
for 15 mins (4). Addition of mAb #1 (50 μg/ml) for
15 min to allow saturation of binding to the immobi-
lized antigen, (5) Addition of a mAb #2 (50 μg/ml) for
15 mins. The ﬁrst antibody (mAb #1) was taken along
to verify the saturation of binding. A 5-minutes washing
step in PBS was included in between steps.
Binding kinetics and aﬃnity measurements. Bind-
ing kinetics and aﬃnity of mAbs to the MERS-S ecto-
domain was measured by BLI using the Octet QK at
25°C. The optimal loading concentration of anti-
MERS-S mAbs onto anti-human Fc biosensors (Pall
ForteBio) was predetermined to avoid saturation of
the sensor. The kinetic binding assay was performed
by loading anti-MERS mAb at optimal concentration
(42 nM) on anti-human Fc biosensor for 10 mins.
Antigen association step was performed by incubating
the sensor with a range of concentrations of the recom-
binant MERS-S ectodomain (200–67 to 22–7.4 nM) for
10 min, followed by a dissociation step in PBS for
60 min. The kinetics constants were calculated using
1:1 Langmuir binding model on Fortebio Data Analysis
7.0 software.
Hemagglutination inhibition assay. The potency of
mAbs to inhibit hemagglutination by MERS-S1A-dis-
playing lumazine synthase nanoparticles (S1A-LS)
was performed as described previously [16], with slight
modiﬁcation. Two-folds serial dilutions of S1A-LS in
PBS containing 0.1% bovine serum albumin (BSA)
were mixed with 0.5% human erythrocyte in V-bottom
96-well plate (Greiner Bio-One), and incubated at 4°C
for 2 h. The hemagglutination titre was scored, and the
concentration of S1A-LS that resulted in 8 hemaggluti-
nation units was determined. Subsequently, two-fold
serial dilutions of anti-MERS-S mAbs in PBS contain-
ing 0.1% BSA were mixed with S1A-LS (8 hemaggluti-
nation units) in a V-bottom 96-well plate. After
30 mins incubation at room temperature, human
erythrocytes were added to a ﬁnal concentration of
0.5% (v/v). The mixture was incubated at 4°C for 2 h
and the hemagglutination inhibition activity by anti-
MERS-S mAbs was scored.
Fusion inhibition assay. Huh-7 cells were seeded
with a density of 105 cells per ml. After reaching 70–
80% conﬂuency, cells were transfected with expression
plasmid encoding full length MERS-CoV S fused to
Green Fluorescence Protein (GFP) using jetPRIME®
(Polyplus transfection, New York, USA; cat no. 114-
07). The furin recognition site in the MERS-CoV S
was mutated to inhibit the cleavage of protein. Two
days post transfection, cells were treated with 10 μg/
ml trypsin (to activate MERS-CoV spike fusion func-
tion) in the presence or absence of 10 μg/ml anti-
MERS-S mAbs. After incubation at 37°C for 2 h, the
cells were ﬁxed by incubation with 4% paraformalde-
hyde in PBS for 20 min at room temperature and
stained for nuclei with 4,6-diamidino-2-phenylindole
(DAPI). Cells expressing MERS-CoV S were detected
by ﬂuorescence microscopy using the C-terminally
appended GFP and MERS-CoV S-mediated cell–cell
fusion was observed by the formation of (ﬂuorescent)
multi-nucleated syncytia. The ﬂuorescence images
were recorded using the EVOS FL ﬂuorescence micro-
scope (Thermo Fisher Scientiﬁc, the Netherlands).
Antibody-mediated protection of mice challenged
with MERS-CoV. In vivo eﬃcacy of mAbs speciﬁc for
the S protein of MERS-CoV, and of an isotype matched
negative controlmAbswas evaluated in the protection of
the transgenic mouse model K18 TghDpp4 expressing
the receptor for the humanMERS-CoV [36] susceptible
to the virulent virus. MERS-CoV intranasal infection of
these transgenic mice expressing human DPP4 causes a
lethal disease associated with encephalitis, lung mono-
nuclear cell inﬁltration, alveolar oedema, and microvas-
cular thrombosis, with airways generally unaﬀected [36].
To test the prophylactic eﬃcacy of mAbs in vivo groups
of 5mice, 20–30weeks old, were given 1.8 mgof the anti-
body per kg mouse by intraperitoneal injection, 6 h
before intranasal infection with a lethal dose of MERS-
CoV (EMC isolate; 5 × 103 pfu/mouse, challenge dose
resulting in consistently lethal infection in untreated
mice). Whereas the administered dose was consistently
lethal for all mice that received the isotype control anti-
body, mice that received the best virus neutralizing anti-
bodies were fully protected.
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